Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -3.15
- Piotroski Score 2.00
- Grade Buy
- Symbol (CELZ)
- Company Creative Medical Technology Holdings, Inc.
- Price $4.25
- Changes Percentage (1.99%)
- Change $0.08
- Day Low $4.02
- Day High $4.39
- Year High $10.28
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.74
- Trailing P/E Ratio -1.17
- Forward P/E Ratio -1.17
- P/E Growth -1.17
- Net Income $-5,286,574
Income Statement
Quarterly
Annual
Latest News of CELZ
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Here's Why Creative Medical Technology Holdings, Inc.'s (NASDAQ:CELZ) CEO Compensation Is The Least Of Shareholders Concerns
Creative Medical Technology Holdings' CEO compensation is considered appropriate given the company's performance. Despite a 73% EPS growth, total shareholder loss over three years was 98%, raising con...
By Yahoo! Finance | 3 months ago
